Tim Chiang
Stock Analyst at Capital One
(1.06)
# 3,880
Out of 5,099 analysts
21
Total ratings
31.25%
Success rate
-5.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Tim Chiang
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HRTX Heron Therapeutics | Initiates: Overweight | $6 | $1.33 | +351.13% | 1 | Apr 23, 2024 | |
| PTGX Protagonist Therapeutics | Initiates: Overweight | n/a | $88.56 | - | 3 | Oct 30, 2023 | |
| JSPR Jasper Therapeutics | Initiates: Overweight | $70 | $1.77 | +3,854.80% | 1 | Aug 11, 2023 | |
| AMPH Amphastar Pharmaceuticals | Initiates: Overweight | $44 | $25.64 | +71.61% | 2 | Jul 29, 2022 | |
| KALA KALA BIO | Maintains: Outperform | $300 → $200 | $0.79 | +25,342.06% | 2 | Mar 30, 2022 | |
| PCRX Pacira BioSciences | Maintains: Market Perform | $75 → $66 | $24.77 | +166.45% | 3 | May 5, 2021 | |
| RPTX Repare Therapeutics | Initiates: Outperform | n/a | $2.16 | - | 1 | Oct 28, 2020 | |
| VRCA Verrica Pharmaceuticals | Initiates: Outperform | $210 | $8.27 | +2,439.30% | 1 | Jun 24, 2020 | |
| TEVA Teva Pharmaceutical Industries | Upgrades: Neutral | n/a | $28.56 | - | 6 | Sep 17, 2018 | |
| SMMT Summit Therapeutics | Initiates: Buy | $33 | $17.02 | +93.89% | 1 | Feb 13, 2018 |
Heron Therapeutics
Apr 23, 2024
Initiates: Overweight
Price Target: $6
Current: $1.33
Upside: +351.13%
Protagonist Therapeutics
Oct 30, 2023
Initiates: Overweight
Price Target: n/a
Current: $88.56
Upside: -
Jasper Therapeutics
Aug 11, 2023
Initiates: Overweight
Price Target: $70
Current: $1.77
Upside: +3,854.80%
Amphastar Pharmaceuticals
Jul 29, 2022
Initiates: Overweight
Price Target: $44
Current: $25.64
Upside: +71.61%
KALA BIO
Mar 30, 2022
Maintains: Outperform
Price Target: $300 → $200
Current: $0.79
Upside: +25,342.06%
Pacira BioSciences
May 5, 2021
Maintains: Market Perform
Price Target: $75 → $66
Current: $24.77
Upside: +166.45%
Repare Therapeutics
Oct 28, 2020
Initiates: Outperform
Price Target: n/a
Current: $2.16
Upside: -
Verrica Pharmaceuticals
Jun 24, 2020
Initiates: Outperform
Price Target: $210
Current: $8.27
Upside: +2,439.30%
Teva Pharmaceutical Industries
Sep 17, 2018
Upgrades: Neutral
Price Target: n/a
Current: $28.56
Upside: -
Summit Therapeutics
Feb 13, 2018
Initiates: Buy
Price Target: $33
Current: $17.02
Upside: +93.89%